Megakaryopoiesis

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 212-219

  Geddis, Amy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INITIATION FACTOR 4E BINDING PROTEIN 1; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN C MYB; PROTEIN KINASE B; PROTEIN P21; RAF PROTEIN; RAP1 PROTEIN; RAS PROTEIN; S6 KINASE; SOS PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; THROMBOPOIETIN; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE DISORDER; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TRANSCRIPTION REGULATION;

HUMANS; MEGAKARYOCYTES; SIGNAL TRANSDUCTION; THROMBOPOIETIN;

EID: 77953903257     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.03.001     Document Type: Article

References (96)

1. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008, 111:981-986.
2. Szalai G., LaRue A.C., Watson D.K. Molecular mechanisms of megakaryopoiesis. Cell Mol Life Sci 2006, 63:2460-2476.
3. Ichikawa M., Asai T., Saito T., et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004, 10:299-304.
4. Elagib K.E., Racke F.K., Mogass M., Khetawat R., Delehanty L.L., Goldfarb A.N. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 2003, 101:4333-4341.
5. Huang H., Yu M., Akie T.E., et al. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol 2009, 29:4103-4115.
6. Nerlov C., Querfurth E., Kulessa H., Graf T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 2000, 95:2543-2551.
7. Chou S.T., Khandros E., Bailey L.C., et al. Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood 2009, 114:983-994.
8. Eisbacher M., Holmes M.L., Newton A., et al. Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. Mol Cell Biol 2003, 23:3427-3441.
9. Starck J., Cohet N., Gonnet C., et al. Functional cross-antagonism between transcription factors FLI-1 and EKLF. Mol Cell Biol 2003, 23:1390-1402.
10. Spyropoulos D.D., Pharr P.N., Lavenburg K.R., et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000, 20:5643-5652.
11. Metcalf D., Carpinelli M.R., Hyland C., et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood 2005, 105:3480-3487.
12. Lu J., Guo S., Ebert B.L., et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008, 14:843-853.
13. Bluteau D., Lordier L., Di Stefano A., et al. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009, 7(Suppl 1):227-234.
14. Raslova H., Roy L., Vourc'h C., et al. Megakaryocyte polyploidization is associated with a functional gene amplification. Blood 2003, 101:541-544.
15. Mattia G., Vulcano F., Milazzo L., et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002, 99:888-897.
16. Corash L., Levin J. The relationship between megakaryocyte ploidy and platelet volume in normal and thrombocytopenic C3H mice. Exp Hematol 1990, 18:985-989.
17. Vitrat N., Cohen-Solal K., Pique C., et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 1998, 91:3711-3723.
18. Geddis A.E., Fox N.E., Tkachenko E., Kaushansky K. Endomitotic megakaryocytes that form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regression. Cell Cycle 2007, 6:455-460.
19. Lordier L., Jalil A., Aurade F., et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood 2008, 112:3164-3174.
20. Nakao K., Angrist A.A. Membrane surface specialization of blood platelet and megakaryocyte. Nature 1968, 217:960-961.
21. Schulze H., Korpal M., Hurov J., et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood 2006, 107:3868-3875.
22. Sharnoff J.G., Scardino V. Pulmonary megakaryocytes in human fetuses and premature and full-term infants. Arch Pathol 1960, 69:139-141.
23. Wright J.H. The histogenesis of blood platelets. J Morphol 1910, 21:263-277.
24. Italiano J.E., Lecine P., Shivdasani R.A., Hartwig J.H. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999, 147:1299-1312.
25. Junt T., Schulze H., Chen Z., et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007, 317:1767-1770.
26. Vigon I., Mornon J.P., Cocault L., et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992, 89:5640-5644.
27. Gurney A.L., Carver-Moore K., de Sauvage F.J., Moore M.W. Thrombocytopenia in c-mpl-deficient mice. Science 1994, 265:1445-1447.
28. Bunting S., Widmer R., Lipari T., et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997, 90:3423-3429.
29. Fox N., Priestley G., Papayannopoulou T., Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 2002, 110:389-394.
30. Alexander W.S., Roberts A.W., Nicola N.A., Li R., Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood 1996, 87:2162-2170.
31. Murone M., Carpenter D.A., de Sauvage F.J. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998, 16:1-6.
32. Sabath D.F., Kaushansky K., Broudy V.C. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999, 94:365-367.
33. Drachman J.G., Kaushansky K. Structure and function of the cytokine receptor superfamily. Curr Opin Hematol 1995, 2:22-28.
34. Dahlen D.D., Broudy V.C., Drachman J.G. Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood 2003, 102:102-108.
35. Hitchcock I.S., Chen M.M., King J.R., Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 2008, 112:2222-2231.
36. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283:987-990.
37. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
38. Drachman J.G., Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A 1997, 94:2350-2355.
39. Geddis A.E., Linden H.M., Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002, 13:61-73.
40. Schulze H., Ballmaier M., Welte K., Germeshausen M. Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets. Exp Hematol 2000, 28:294-304.
41. Matsumura I., Ishikawa J., Nakajima K., et al. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. Mol Cell Biol 1997, 17:2933-2943.
42. Kirito K., Watanabe T., Sawada K., Endo H., Ozawa K., Komatsu N. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 2002, 277:8329-8337.
43. Magne S., Caron S., Charon M., Rouyez M.C., Dusanter-Fourt I. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol Cell Biol 2003, 23:8934-8945.
44. Harir N., Pecquet C., Kerenyi M., et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 2007, 109:1678-1686.
45. Najfeld V., Cozza A., Berkofsy-Fessler W., Prchal J., Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007, 35:1668-1676.
46. Rouyez M.C., Boucheron C., Gisselbrecht S., Dusanter-Fourt I., Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol 1997, 17:4991-5000.
47. Rojnuckarin P., Drachman J.G., Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999, 94:1273-1282.
48. Fichelson S., Freyssinier J.M., Picard F., et al. Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors. Blood 1999, 94:1601-1613.
49. Miyakawa Y., Oda A., Druker B.J., et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995, 86:23-27.
50. Alexander W.S., Maurer A.B., Novak U., Harrison-Smith M. Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J 1996, 15:6531-6540.
51. Skolnik E.Y., Batzer A., Li N., et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993, 260:1953-1955.
52. Avruch J., Khokhlatchev A., Kyriakis J.M., et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001, 56:127-155.
53. Luoh S.M., Stefanich E., Solar G., et al. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Mol Cell Biol 2000, 20. 507-5.
54. Brizzi M.F., Dentelli P., Lanfrancone L., Rosso A., Pelicci P.G., Pegoraro L. Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation. Oncogene 1996, 13:2067-2076.
55. Garcia J., de Gunzburg J., Eychene A., Gisselbrecht S., Porteu F. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways. Mol Cell Biol 2001, 21:2659-2670.
56. Geddis A.E., Fox N.E., Kaushansky K. Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem 2001, 276:34473-34479.
57. Miyakawa Y., Rojnuckarin P., Habib T., Kaushansky K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem 2001, 276:2494-2502.
58. Kodaki T., Woscholski R., Hallberg B., Rodriguez-Viciana P., Downward J., Parker P.J. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994, 4:798-806.
59. Nakao T., Geddis A.E., Fox N.E., Kaushansky K. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 2007, 7:257-266.
60. Soda M., Willert K., Kaushansky K., Geddis A.E. Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway. Cell Signal 2008, 20:2317-2323.
61. Raslova H., Baccini V., Loussaief L., et al. Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood 2006, 107:2303-2310.
62. Guerriero R., Parolini I., Testa U., et al. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci 2006, 119:744-752.
63. Zhang J., Grindley J.C., Yin T., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
64. Starr R., Willson T.A., Viney E.M., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
65. Endo T.A., Masuhara M., Yokouchi M., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
66. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004, 22:503-529.
67. Wang Q., Miyakawa Y., Fox N., Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000, 96:2093-2099.
68. Hookham M.B., Elliott J., Suessmuth Y., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007, 109:4924-4929.
69. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004, 200:569-580.
70. Seita J., Ema H., Ooehara J., et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A 2007, 104:2349-2354.
71. Bersenev A., Wu C., Balcerek J., Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008, 118:2832-2844.
72. Funakoshi-Tago M., Pelletier S., Matsuda T., Parganas E., Ihle J.N. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J 2006, 25:4763-4772.
73. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
74. Owen C.J., Toze C.L., Koochin A., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008, 112:4639-4645.
75. Ciovacco W.A., Raskind W.H., Kacena M.A. Human phenotypes associated with GATA-1 mutations. Gene 2008, 427:1-6.
76. Grossfeld P.D., Mattina T., Lai Z., et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 2004, 129A:51-61.
77. Raslova H., Komura E., Le Couedic J.P., et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest 2004, 114:77-84.
78. Ihara K., Ishii E., Eguchi M., et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999, 96:3132-3136.
79. Ballmaier M., Germeshausen M., Schulze H., et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001, 97:139-146.
80. Ballmaier M., Germeshausen M., Krukemeier S., Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003, 996:17-25.
81. King S., Germeshausen M., Strauss G., Welte K., Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005, 131:636-644.
82. Wiestner A., Schlemper R.J., van der Maas A.P., Skoda R.C. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998, 18:49-52.
83. Kondo T., Okabe M., Sanada M., et al. Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood 1998, 92:1091-1096.
84. Ding J., Komatsu H., Wakita A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103:4198-4200.
85. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
86. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
87. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
88. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
89. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
90. Boissinot M., Lippert E., Girodon F., et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006, 108:3223-3224.
91. De Stefano V., Fiorini A., Rossi E., et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007, 5:708-714.
92. Yan X.Q., Lacey D., Hill D., et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996, 88:402-409.
93. Chagraoui H., Komura E., Tulliez M., Giraudier S., Vainchenker W., Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
94. Theocharides A., Boissinot M., Girodon F., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375-379.
95. Kralovics R., Stockton D.W., Prchal J.T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003, 102:3793-3796.
96. Skoda R., Prchal J.T. Lessons from familial myeloproliferative disorders. Semin Hematol 2005, 42:266-273.